Thyroid and Bone

Endocrinology and Metabolism Clinics of North America

Volumn 36, Issue 3, 2007, Pages 673-705

  Wexler, Jason A ^a   Sharretts, John ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALKALINE PHOSPHATASE; ANTITHYROID AGENT; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 10; COLLAGEN TYPE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; IODINE 131; LEVOTHYROXINE; LIOTHYRONINE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE RELATED PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RADIOACTIVE IODINE; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; SOMATOMEDIN C; THIAMAZOLE; THYROID HORMONE RECEPTOR; THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR BETA; THYROTROPIN; THYROTROPIN RECEPTOR; THYROXINE DEIODINASE; UNINDEXED DRUG; VITAMIN D RECEPTOR; WNT PROTEIN;

BONE DENSITY; BONE DEVELOPMENT; BONE DISEASE; BONE GROWTH; BONE METASTASIS; BONE MINERALIZATION; BONE REMODELING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; CRYOTHERAPY; DISEASE ASSOCIATION; FRACTURE; GENE EXPRESSION; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; POSTMENOPAUSE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; THYROID CANCER; THYROID DISEASE; THYROIDECTOMY;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE DEVELOPMENT; BONE NEOPLASMS; BONE REMODELING; DIPHOSPHONATES; FRACTURES, BONE; HUMANS; HYPERTHYROIDISM; IODINE RADIOISOTOPES; RECEPTORS, THYROID HORMONE; THYROID DISEASES; THYROID GLAND; THYROID NEOPLASMS; THYROXINE;

EID: 34547300704     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2007.04.005     Document Type: Review

References (188)

1. Galliford T.M., Murphy E., Williams A.J., et al. Effects of thyroid status on bone metabolism: a primary role for thyroid stimulating hormone or thyroid hormone?. Minerva Endocrinol 30 (2005) 237
2. Kronenberg H.M. Developmental regulation of the growth plate. Nature 423 (2003) 332
3. Bassett J.H., Swinhoe R., Chassande O., et al. Thyroid hormone regulates heparin sulfate proteoglycan expression in the growth plate. Endocrinology 147 (2006) 295
4. Eriksen E.F., Mosekilde L., and Melsen F. Trabecular bone remodeling and bone balance in hyperthyroidism. Bone 6 (1985) 421
5. Bassett J.H., and Williams G.R. The molecular actions of thyroid hormone in bone. Trends Endocrinol Metab 14 (2003) 356
6. Robson H., Siebler T., Stevens D.A., et al. Thyroid hormone acts directly on growth plate chondrocytes to promote hypertrophic differentiation and inhibit clonal expansion and cell proliferation. Endocrinology 141 (2000) 3887
7. Stevens D.A., Hasserjian R.P., Robson H., et al. Thyroid hormones regulate hypertrophic chondrocyte differentiation and expression of parathyroid hormone-related peptide and its receptor during endochondral bone formation. J Bone Miner Res 15 (2000) 2431
8. Abu E., Bord S., Horner A., et al. The expression of thyroid hormone receptors in human bone. Bone 21 (1997) 137
9. Abu E., Horner A., Teti A., et al. The localization of thyroid hormone receptor mRNAs in human bone. Thyroid 10 (2000) 287
10. Allain T.J., Yen P.M., Flanagan A.M., et al. The isoform-specific expression of the tri-iodothyronine receptor in osteoblasts and osteoclasts. Eur J Clin Invest 26 (1996) 418
11. Siddiqi A., Parsons M.P., Lewis J.L., et al. TR expression and function in human bone marrow stromal and osteoblast-like cells. J Clin Endocrinol Metab 87 (2002) 906
12. Williams G.R., Bland R., and Sheppard M.C. Characterization of thyroid hormone (T3) receptors in three osteosarcoma cell lines of distinct osteoblast phenotype: interactions among T3, vitamin D3, and retinoid signaling. Endocrinology 135 (1994) 2375
13. Abe E., Marians R., Yu W., et al. TSH is a negative regulator of skeletal remodeling. Cell 115 (2003) 151
14. Morimura T., Tsunekawa K., Kasahara T., et al. Expression of type 2 iodothyronine deiodinase in human osteoblast is stimulated by thyrotropin. Endocrinology 146 (2005) 2077
15. Weiss R.E., and Refetoff S. Effect of thyroid hormone on growth: lessons from the syndrome of resistance to thyroid hormone. Endocrinol Metab Clin North Am 25 (1996) 719
16. Ishikawa Y., Genge B.R., Wuthier R.E., et al. Thyroid hormone inhibits growth and stimulates terminal differentiation of epiphyseal growth plate chondrocytes. J Bone Miner Res 13 (1998) 1398
17. Miura M., Tanaka K., Komatsu Y., et al. Thyroid hormones promote chondrocyte differentiation in mouse ATDC5 cells and stimulate endochondral ossification in fetal mouse tibias through iodothyronine deiodinases in the growth plate. J Bone Miner Res 17 (2002) 443
18. Okubo Y., and Reddi A.H. Thyroxine downregulates Sox9 and promotes chondrocyte hypertrophy. Biochem Biophys Res Commun 306 (2003) 186
19. Lakatos P., Foldes J., Horvath C., et al. Serum interleukin-6 and bone metabolism in patients with thyroid function disorders. J Clin Endocrinol Metab 82 (1997) 78
20. Lakatos P., Foldes J., Nagy Z., et al. Serum insulin-like growth factor-I, insulin-like growth factor binding proteins, and bone mineral content in hyperthyroidism. Thyroid 10 (2000) 417
21. Dentice M., Bandyopadhyay A., Gereben B., et al. The Hedgehog-inducible ubiquitin ligase subunit WSB-1 modulates thyroid hormone activation and PTHrP secretion in the developing growth plate. Nat Cell Biol 7 (2005) 698
22. Shao Y.Y., Wang L., Hicks D.G., et al. Expression and activation of peroxisome proliferator-activated receptors in growth plate chondrocytes. J Orthop Res 23 (2005) 1139
23. Wang L., Shao Y.Y., and Ballock R.T. Peroxisome proliferator activated receptor-gamma (PPARgamma) represses thyroid hormone signaling in growth plate chondrocytes. Bone 37 (2005) 305
24. O'Shea P.J., and Williams G.R. Insight into the physiological actions of thyroid hormone receptors from genetically modified mice. J Endocrinol 175 (2002) 553
25. Gauthier K., Chassande O., Plateroti M., et al. Different functions for the thyroid hormone receptors TRalpha and TRbeta in the control of thyroid hormone production and post-natal development. EMBO J 18 (1999) 623
26. Mundy G., Shapiro J., Bandelin J., et al. Direct stimulation of bone resorption by thyroid hormones. J Clin Invest 58 (1976) 529
27. Allain T.J., and McGregor A.M. Thyroid hormones and bone. J Endocrinol 139 (1993) 9
28. Kanatani M., Sugimoto T., Sowa H., et al. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction. J Cell Physiol 201 (2004) 17
29. Freitas F.R., Moriscot A.S., Jorgetti V., et al. Spared bone mass in rats treated with thyroid hormone receptor TR beta-selective compound GC-1. Am J Physiol Endocrinol Metab 285 (2003) E1135
30. Mosekilde L., Eriksen E., and Charles P. Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin North Am 19 (1990) 35
31. Harvey C.B., O'Shea P.J., Scott A.J., et al. Molecular mechanisms of thyroid hormone effects on bone growth and function. Mol Genet Metab 75 (2002) 17
32. Milne M., Quail J.M., Rosen C.J., et al. Insulin-like growth factor binding proteins in femoral and vertebral bone marrow stromal cells: expression and regulation by thyroid hormone and dexamethasone. J Cell Biochem 81 (2001) 229
33. Siddiqi A., Burrin J.M., Wood D.F., et al. Tri-iodothyronine regulates the production of interleukin-6 and interleukin-8 in human bone marrow stromal and osteoblast-like cells. J Endocrinol 157 (1998) 453
34. Simsek G., Karter Y., Aydin S., et al. Osteoporotic cytokines and bone metabolism on rats with induced hyperthyroidism; changes as a result of reversal to euthyroidism. Chin J Physiol 46 (2003) 181
35. Stevens D.A., Harvey C.B., Scott A.J., et al. Thyroid hormone activates fibroblast growth factor receptor-1 in bone. Mol Endocrinol 17 (2003) 1751
36. Hase H., Ando T., Eldeiry L., et al. TNFalpha mediates the skeletal effects of thyroid-stimulating hormone. Proc Natl Acad Sci U S A 103 (2006) 12849
37. Sun L., Davies T., Blair H., et al. TSH and bone loss. Ann N Y Acad Sci 1068 (2006) 309
38. Mazziotti G., Sorvillo F., Piscopo M., et al. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. J Bone Miner Res 20 (2005) 480
39. Majima T., Komatsu Y., Doi K., et al. Negative correlation between bone mineral density and TSH receptor antibodies in male patients with untreated Graves' disease. Osteoporos Int 17 (2006) 1103
40. Franklyn J., Maisonneuve P., Sheppard M., et al. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med 338 (1998) 712
41. Vestergaard P., Rejnmark L., Weeke J., et al. Fracture risk in patients treated for hyperthyroidism. Thyroid 10 (2000) 341
42. Melton III L.J., Ardila E., Crowson C.S., et al. Fractures following thyroidectomy in women: a population-based cohort study. Bone 27 (2000) 695
43. Nguyen T.T., Heath III H., Bryant S.C., et al. Fractures after thyroidectomy in men: a population-based cohort study. J Bone Miner Res 12 (1997) 1092
44. Vestergaard P., and Mosekilde L. Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. Thyroid 12 (2002) 411
45. Vestergaard P., Rejnmark L., and Mosekilde L. Influence of hyper- and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk. Calcif Tissue Int 77 (2005) 139
46. Bauer D., Ettinger B., Nevitt M., et al. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 134 (2001) 561
47. Wejda B., Hintze G., Katschinski B., et al. Hip fractures and the thyroid: a case-control study. J Intern Med 237 (1995) 241
48. Solomon B., Wartofsky L., and Burman K. Prevalence of fractures in postmenopausal women with thyroid disease. Thyroid 3 (1993) 17
49. Vestergaard P., Weeke J., Hoeck H., et al. Fractures in patients with primary idiopathic hypothyroidism. Thyroid 10 (2000) 335
50. Leese G., Jung R., Guthrie C., et al. Morbidity in patients on L-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH. Clin Endocrinol (Oxf) 37 (1992) 500
51. Linde J., and Friis T. Osteoporosis in hyperthyroidism estimated by photon absorptiometry. Acta Endocrinol (Copenh) 91 (1979) 437
52. Krolner B., Jorgensen J., and Nielsen S. Spinal bone mineral content in myxoedema and thyrotoxicosis: effects of thyroid hormone(s) and antithyroid treatment. Clin Endocrinol (Oxf) 18 (1983) 439
53. Toh S., Claunch B., and Brown P. Effect of hyperthyroidism and its treatment on bone mineral content. Arch Intern Med 145 (1985) 883
54. Acotto C.G., Niepomniszcze H., Vega E., et al. Ultrasound parameters and markers of bone turnover in hyperthyroidism: a longitudinal study. J Clin Densitom 7 (2004) 201
55. Diamond T., Vine J., Smart R., et al. Thyrotoxic bone disease in women: a potentially reversible disorder. Ann Intern Med 120 (1994) 8
56. Rosen C., and Adler R. Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism. J Clin Endocrinol Metab 75 (1992) 1531
57. Karga H., Papapetrou P., Korakovoni A., et al. Bone mineral density in hyperthyroidism. Clin Endocrinol (Oxf) 61 (2004) 466
58. Langdahl B., Loft A., Eriksen E., et al. Bone mass, bone turnover, body composition, and calcium homeostasis in former hyperthyroid patients treated by combined medical therapy. Thyroid 6 (1996) 161
59. Langdahl B., Loft A., Eriksen E., et al. Bone mass, bone turnover, calcium homeostasis, and body composition in surgically and radioiodine-treated former hyperthyroid patients. Thyroid 6 (1996) 169
60. Nielsen H., Mosekilde L., and Charles P. Bone mineral content in hyperthyroid patients after combined medical and surgical treatment. Acta Radiol Oncol Radiat Phys Biol 18 (1979) 122
61. Grant D., McMurdo M., Mole P., et al. Is previous hyperthyroidism still a risk factor for osteoporosis in post-menopausal women?. Clin Endocrinol (Oxf) 43 (1995) 339
62. Lupoli G., Nuzzo V., Di Carlo C., et al. Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole. Gynecol Endocrinol 10 (1996) 343
63. Majima T., LKomatsu Y., Doi K., et al. Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease. J Bone Miner Metab 24 (2006) 105
64. Rosen H., Moses A., Gundberg C., et al. Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans. J Clin Endocrinol Metab 77 (1993) 664
65. Kung A., and Ng F. A rat model of thyroid hormone-induced bone loss: effect of antiresorptive agents on regional bone density and osteocalcin gene expression. Thyroid 4 (1994) 93
66. Rosen H., Sullivan E., Middlebrooks V., et al. Parenteral pamidronate prevents thyroid hormone-induced bone loss in rats. J Bone Miner Res 8 (1993) 1255
67. Franklyn J., Betteridge J., Holder R., et al. Effect of estrogen replacement therapy upon bone mineral density in thyroxine-treated postmenopausal women with a past history of thyrotoxicosis. Thyroid 5 (1995) 359
68. Akcay M.N., Akcay G., and Habib B. The effects of calcitonin on bone resorption in hyperthyroidism: a placebo-controlled clinical study. J Bone Miner Metab 22 (2004) 90
69. Jodar E., Munoz-Torres M., Escobar-Jimenez F., et al. Antiresorptive therapy in hyperthyroid patients: longitudinal changes in bone and mineral metabolism. J Clin Endocrinol Metab 82 (1997) 1989
70. Hawkins F., Escobar-Jimenez F., Jodar E., et al. Bone mineral density in hypoparathyroid women on LT4 suppressive therapy: effect of calcium and 1,25(OH)2 vitamin D3 treatment. J Musculoskelet Neuronal Interact 3 (2003) 71
71. Bauer D., Nevitt M., Ettinger B., et al. Low thyrotropin levels are not associated with bone loss in older women: a prospective study. J Clin Endocrinol Metab 82 (1997) 2931
72. Faber J., Overgaard K., Jarlov A., et al. Bone metabolism in premenopausal women with nontoxic goiter and reduced serum thyrotropin levels. Thyroidology 6 (1994) 27
73. Gurlek A., and Gedik O. Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Thyroid 9 (1999) 539
74. Ugur-Altun B., Altun A., Arikan E., et al. Relationships existing between the serum cytokine levels and bone mineral density in women in the premenopausal period affected by Graves' disease with subclinical hyperthyroidism. Endocr Res 29 (2003) 389
75. Faber J., Jensen I., Petersen L., et al. Normalization of serum thyrotropin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin Endocrinol (Oxf) 48 (1998) 285
76. Foldes J., Tarjan G., Szathmari M., et al. Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis?. Clin Endocrinol (Oxf) 39 (1993) 521
77. Foldes J., Lakatos P., Zsadanyi J., et al. Decreased serum IGF-I and dehydroepiandrosterone sulphate may be risk factors for the development of reduced bone mass in postmenopausal women with endogenous subclinical hyperthyroidism. Eur J Endocrinol 136 (1997) 277
78. Tauchmanova L., Nuzzo V., Del Puente A., et al. Reduced bone mass detected by bone quantitative ultrasonometry and DEXA in pre- and postmenopausal women with endogenous subclinical hyperthyroidism. Maturitas 48 (2004) 299
79. Lee W.Y., Oh K.W., Rhee E.J., et al. Relationship between subclinical thyroid dysfunction and femoral neck bone mineral density in women. Arch Med Res 37 (2006) 511
80. Mudde A., Houben A., and Nieuwenhuijzen Kruseman A. Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol (Oxf) 41 (1994) 421
81. Chen C.H., Chen J.F., Yang B.Y., et al. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma. J Formos Med Assoc 103 (2004) 442
82. De Rosa G., Testa A., Giacomini D., et al. Prospective study of bone loss in pre- and post-menopausal women on L-thyroxine therapy for non-toxic goitre. Clin Endocrinol (Oxf) 47 (1997) 529
83. Diamond T., Nery L., and Hales I. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab 72 (1991) 1184
84. Franklyn J., Betteridge J., Holder R., et al. Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis. Clin Endocrinol (Oxf) 41 (1994) 425
85. Garton M., Reid I., Loveridge N., et al. Bone mineral density and metabolism in premenopausal women taking L-thyroxine replacement therapy. Clin Endocrinol (Oxf) 41 (1994) 747
86. Giannini S., Nobile M., Sartori L., et al. Bone density and mineral metabolism in thyroidectomized patients treated with long-term L-thyroxine. Clin Sci (Lond) 87 (1994) 593
87. Gonzalez D., Marutalen C., Correa P., et al. Bone mass in totally thyroidectomized patients: role of calcitonin deficiency and exogenous thyroid treatment. Acta Endocrinol (Copenh) 124 (1991) 521
88. Jodar E., Begona Lopez M., Garcia L., et al. Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass. Osteoporos Int 8 (1998) 311
89. Karner I., Hrgovic Z., Sijanovic S., et al. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine. Eur J Med Res 10 (2005) 480
90. Khmara I.M., and Tolkachev Iu V. [Bone tissue mineral density in patients with thyroid gland cancer on levothyroxine natrium therapy]. Klin Med (Mosk) 83 (2005) 61 [in Russian]
91. Kung A., and Yeung S. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. J Clin Endocrinol Metab 81 (1996) 1232
92. Kung A.W., Lorentz T., and Tam S.C. Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women. Clin Endocrinol (Oxf) 39 (1993) 535
93. Lehmke J., Bogner U., Felsenberg D., et al. Determination of bone mineral density by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopaenia in post-menopausal women. Clin Endocrinol (Oxf) 36 (1992) 511
94. Mazokopakis E.E., Starakis I.K., Papadomanolaki M.G., et al. Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy. Curr Med Res Opin 22 (2006) 1369
95. McDermott M.T., Perloff J.J., and Kidd G.S. A longitudinal assessment of bone loss in women with levothyroxine-suppressed benign thyroid disease and thyroid cancer. Calcif Tissue Int 56 (1995) 521
96. Muller C., Bayley T., Harrison J., et al. Possible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance. Thyroid 5 (1995) 81
97. Paul T., Kerrigan J., Kelly A., et al. Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women. JAMA 259 (1988) 3137
98. Piolo G., Pedrazzoni M., Palummeri E., et al. Longitudinal study of bone loss after thyroidectomy and suppressive thyroxine therapy in premenopausal women. Acta Endocrinol (Copenh) 126 (1992) 238
99. Ross D., Neer R., Ridgway E., et al. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med 82 (1987) 1167
100. Schneider D., Barrett-Connor E., and Morton D. Thyroid hormone use and bone mineral density in elderly women: effects of estrogen. JAMA 271 (1994) 1245
101. Stall G., Harris S., Sokoll L., et al. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine. Ann Intern Med 113 (1990) 265
102. Stepan J., and Limanova Z. Biochemical assessment of bone loss in patients on long-term thyroid hormone treatment. Bone Miner 17 (1992) 377
103. Appetecchia M. Effects on bone mineral density by treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine in a cohort women study. Horm Res 64 (2005) 293
104. Baldini M., Gallazzi M., Orsatti A., et al. Treatment of benign nodular goitre with mildly suppressive doses of L-thyroxine: effects on bone mineral density and on nodule size. J Intern Med 251 (2002) 407
105. Bauer M., Fairbanks L., Berghofer A., et al. Bone mineral density during maintenance treatment with supraphysiological doses of levothyroxine in affective disorders: a longitudinal study. J Affect Disord 83 (2004) 183
106. De Rosa G., Testa A., Maussier M., et al. A slightly suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goitre. Horm Metab Res 27 (1995) 503
107. Florkowski C.M., Brownlie B.E., Elliot J.R., et al. Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma. N Z Med J 106 (1993) 443
108. Franklyn J., Betteridge J., Daykin J., et al. Long-term thyroxine treatment and bone mineral density. Lancet 340 (1992) 9
109. Gorres G., Kaim A., Otte A., et al. Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma. Eur J Nucl Med 23 (1996) 690
110. Grant D.J., McMurdo M.E., Mole P.A., et al. Suppressed TSH levels secondary to thyroxine replacement therapy are not associated with osteoporosis. Clin Endocrinol (Oxf) 39 (1993) 529
111. Guo C., Weetman A., and Eastell R. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin Endocrinol (Oxf) 46 (1997) 301
112. Hawkins F., Rigopoulou D., Papapietro K., et al. Spinal bone mass after long-term treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis. Calcif Tissue Int 54 (1994) 16
113. Heijckmann A.C., Huijberts M.S., Geusens P., et al. Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma. Eur J Endocrinol 153 (2005) 23
114. Larijani B., Gharibdoost F., Pajouhi M., et al. Effects of levothyroxine suppressive therapy on bone mineral density in premenopausal women. J Clin Pharm Ther 29 (2004) 1
115. Marcocci C., Golia F., Bruno-Bossio G., et al. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women. J Clin Endocrinol Metab 78 (1994) 818
116. Marcocci C., Golia F., Vignali E., et al. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine. J Bone Miner Metab 12 (1997) 72
117. Nuzzo V., Lupoli G., Esposito Del Puente A., et al. Bone mineral density in premenopausal women receiving levothyroxine suppressive therapy. Gynecol Endocrinol 12 (1998) 333
118. Rosen H., Moses A., Garber J., et al. Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate. J Clin Endocrinol Metab 83 (1998) 2324
119. Sajjinanont T., Rajchadara S., Sriassawaamorn N., et al. The comparative study of bone mineral density between premenopausal women receiving long term suppressive doses of levothyroxine for well-differentiated thyroid cancer with healthy premenopausal women. J Med Assoc Thai 88 Suppl 3 (2005) S71
120. Toh S., and Brown P. Bone mineral content in hypothyroid male patients with hormone replacement: a 3-year study. J Bone Miner Res 5 (1990) 463
121. Coindre J., David J., Riviere L., et al. Bone loss in hypothyroidism with hormone replacement: a histomorphometric study. Arch Intern Med 146 (1986) 48
122. Meier C., Beat M., Guglielmetti M., et al. Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized controlled trial. Osteoporos Int 15 (2004) 209
123. Ribot C., Tremollieres F., Pouilles J., et al. Bone mineral density and thyroid hormone therapy. Clin Endocrinol (Oxf) 33 (1990) 143
124. Kung A., and Pun K. Bone mineral density in premenopausal women receiving long-term physiological doses of levothyroxine. JAMA 265 (1991) 2688
125. Ross D. Bone density is not reduced during the short-term administration of levothyroxine to postmenopausal women with subclinical hypothyroidism: a randomized, prospective study. Am J Med 95 (1993) 385
126. Hadji P., Hars O., Sturm G., et al. The effect of long-term, non-suppressive levothyroxine treatment on quantitative ultrasonometry of bone in women. Eur J Endocrinol 142 (2000) 445
127. Hanna F., Pettit R., Ammari F., et al. Effect of replacement doses of thyroxine on bone mineral density. Clin Endocrinol (Oxf) 48 (1998) 229
128. Langdahl B., Loft A., Eriksen E., et al. Bone mass, bone turnover and body composition in former hypothyroid patients receiving replacement therapy. Eur J Endocrinol 134 (1996) 702
129. Schneider D., Barrett-Connor E., and Morton D. Thyroid hormone use and bone mineral density in elderly men. Arch Intern Med 155 (2005) 1995
130. Salerno M., Lettiero T., Esposito-del Puente A., et al. Effect of long-term L-thyroxine treatment on bone mineral density in young adults with congenital hypothyroidism. Eur J Endocrinol 151 (2004) 689
131. Faber J., and Galloe A. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 130 (1994) 350
132. Uzzan B., Campos J., Cucherat M., et al. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 81 (1996) 4278
133. Ross D. Hyperthyroidism, thyroid hormone therapy, and bone. Thyroid 4 (1994) 319
134. Quan M.L., Pasieka J.L., and Rorstad O. Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature. J Surg Oncol 79 (2002) 62
135. Heemstra K.A., Hamdy N.A., Romijn J.A., et al. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Thyroid 16 (2006) 583
136. Schneider R., and Reiners C. The effect of levothyroxine therapy on bone mineral density: a systematic review of the literature. Exp Clin Endocrinol Diabetes 111 (2003) 455
137. Amato G., Mazziotti G., Sorvillo F., et al. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. Bone 35 (2004) 785
138. Cooper D., Kaplan M., Ridgway E., et al. Alkaline phosphatase isoenzyme patterns in hyperthyroidism. Ann Intern Med 90 (1979) 164
139. MacLeod J., McHardy K., Harvey R., et al. The early effects of radioiodine therapy for hyperthyroidism on biochemical indices of bone turnover. Clin Endocrinol (Oxf) 38 (1993) 49
140. Mochizuki Y., Banba N., Hattori Y., et al. Correlation between serum osteoprotegerin and biomarkers of bone metabolism during anti-thyroid treatment in patients with Graves' disease. Horm Res 66 (2006) 236
141. Mosekilde L., Christensen M., Melsen F., et al. Effect of antithyroid treatment on calcium-phosphorus metabolism in hyperthyroidism. I: chemical quantities in serum and urine. Acta Endocrinol (Copenh) 87 (1978) 743
142. Mosekilde L., Melsen F., Bagger J., et al. Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism. Acta Endocrinol (Copenh) 85 (1977) 515
143. Nagasaka S., Sugimoto H., Nakamura T., et al. Antithyroid therapy improves bony manifestations and bone metabolic markers in patients with Graves' thyrotoxicosis. Clin Endocrinol (Oxf) 47 (1997) 215
144. Kumeda Y., Inaba M., Tahara H., et al. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 85 (2000) 4157
145. Loviselli A., Rizzolo E., Mastinu R., et al. High serum circulating telopeptide type I in multinodular goiter. Horm Metab Res 35 (2003) 377
146. Kisakol G., Kaya A., Gonen S., et al. Bone and calcium metabolism in subclinical autoimmune hyperthyroidism and hypothyroidism. Endocr J 50 (2003) 657
147. Sekeroglu M.R., Altun Z.B., Algun E., et al. Serum cytokines and bone metabolism in patients with thyroid dysfunction. Adv Ther 23 (2006) 475
148. Harvey R., McHardy K., Reid D., et al. Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers. J Clin Endocrinol Metab 72 (1991) 1189
149. Mikosch P., Jauk B., Gallowitsch H., et al. Suppressive levothyroxine therapy has no significant influence on bone degradation in women with thyroid carcinoma: a comparison with other disorders affecting bone metabolism. Thyroid 11 (2001) 257
150. Mikosch P., Obermayer-Pietsch B., Jost R., et al. Bone metabolism in patients with differentiated thyroid carcinoma receiving suppressive levothyroxine treatment. Thyroid 13 (2003) 347
151. Ross D., Ardisson L., Nussbaum S., et al. Serum osteocalcin in patients taking L-thyroxine who have subclinical hyperthyroidism. J Clin Endocrinol Metab 72 (1991) 507
152. Schneider P., Berger P., Kruse K., et al. Effect of calcitonin deficiency on bone density and bone turnover in totally thyroidectomized patients. J Endocrinol Invest 14 (1991) 935
153. Guang-Da X., Hui-Ling S., Zhi-Song C., et al. Alteration of plasma concentrations of OPG before and after levothyroxine replacement therapy in hypothyroid patients. J Endocrinol Invest 28 (2005) 965
154. Guang-da X., Hui-ling S., Zhi-song C., et al. Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients. J Clin Endocrinol Metab 90 (2005) 5765
155. Hundahl S.A., Fleming I.D., Fremgen A.M., et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. [see comments]. Cancer 83 (1998) 2638
156. Pacini F., Schlumberger M., Dralle H., et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154 (2006) 787
157. Conacci-Sorrell M., Zhurinsky J., and Ben-Ze'ev A. The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest 109 (2002) 987
158. Lipton A. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention. J Support Oncol 2 (2004) 205
159. Aldred M.A., Ginn-Pease M.E., Morrison C.D., et al. Caveolin-1 and caveolin-2,together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis. Cancer Res 63 (2003) 2864
160. Aldred M.A., Huang Y., Liyanarachchi S., et al. Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol 22 (2004) 3531
161. Owens L.V., Xu L., Dent G.A., et al. Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer. Ann Surg Oncol 3 (1996) 100
162. Bellahcene A., Albert V., Pollina L., et al. Ectopic expression of bone sialoprotein in human thyroid cancer. Thyroid 8 (1998) 637
163. Chen K.T., Lin J.D., Chao T.C., et al. Identifying differentially expressed genes associated with metastasis of follicular thyroid cancer by cDNA expression array. Thyroid 11 (2001) 41
164. Pecheur I., Peyruchaud O., Serre C.M., et al. Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 16 (2002) 1266
165. Bernier M.O., Leenhardt L., Hoang C., et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 86 (2001) 1568
166. Marcocci C., Pacini F., Elisei R., et al. Clinical and biologic behavior of bone metastases from differentiated thyroid carcinoma. Surgery 106 (1989) 960
167. Zettinig G., Fueger B.J., Passler C., et al. Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma: surgery or conventional therapy?. Clin Endocrinol (Oxf) 56 (2002) 377
168. Orr F.W., Lee J., Duivenvoorden W.C., et al. Pathophysiologic interactions in skeletal metastasis. Cancer 88 (2000) 2912
169. Roodman G.D. Mechanisms of bone metastasis. N Engl J Med 350 (2004) 1655
170. Castillo L.A., Yeh S.D., Leeper R.D., et al. Bone scans in bone metastases from functioning thyroid carcinoma. Clin Nucl Med 5 (1980) 200
171. Guise T.A., and Mundy G.R. Cancer and bone. Endocr Rev 19 (1998) 18
172. Matsumoto T., and Abe M. Bone destruction in multiple myeloma. Ann N Y Acad Sci 1068 (2006) 319
173. Bodine P.V., and Komm B.S. Wnt signaling and osteoblastogenesis. Rev Endocr Metab Disord 7 (2006) 33-39
174. Mikosch P., Igerc I., Kudlacek S., et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin in men with thyroid cancer. Eur J Clin Invest 36 (2006) 566
175. Brage M.E., and Simon M.A. Evaluation, prognosis, and medical treatment considerations of metastatic bone tumors. Orthopedics 15 (1992) 589
176. Iwata M., Kasagi K., Misaki T., et al. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging 31 (2004) 491
177. Schlumberger M., Challeton C., De Vathaire F., et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 37 (1996) 598
178. Durante C., Haddy N., Baudin E., et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91 (2006) 2892
179. Vitale G., Fonderico F., Martignetti A., et al. Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Br J Cancer 84 (2001) 1586
180. Rosen L.S., Gordon D.H., Dugan Jr. W., et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100 (2004) 36
181. In: Wartofsky L., and Van Norstrand D. (Eds). Thyroid cancer: a comprehensive guide to clinical management. 2nd edition (2006), Humana Press, Totowa (NJ)
182. Bilezikian J.P. Osteonecrosis of the jaw: do bisphosphonates pose a risk?. N Engl J Med 355 (2006) 2278
183. Woo S.B., Hellstein J.W., and Kalmar J.R. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 (2006) 753
184. Frassica D.A. General principles of external beam radiation therapy for skeletal metastases. Clinical Orthopaedics & Related Research 415 (2003) S158-S164
185. Monchik J.M., Donatini G., Iannuccilli J., et al. Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma. Ann Surg 244 (2006) 296
186. Tsang R.W., Brierley J.D., Simpson W.J., et al. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 82 (1998) 375
187. Brierley J.D., and Tsang R.W. External-beam radiation therapy in the treatment of differentiated thyroid cancer. Semin Surg Oncol 16 (1999) 42
188. Robinson D., Yassin M., and Nevo Z. Cryotherapy of musculoskeletal tumors: from basic science to clinical results. Technol Cancer Res Treat 3 (2004) 371